Related Experiment Video

Updated: May 3, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

631

[Pediatric Crohn's disease in Tunisia]

N Siala, A Benzarti, S Boukthir

    La Tunisie Medicale
    |January 25, 2014
    PubMed

    Insights

    Pediatric Crohn's disease in Tunisia presents unique characteristics, often with delayed diagnosis. Management relies on immunosuppressive therapy and nutritional support for affected children.

    Area of Science:

    • Pediatric gastroenterology
    • Inflammatory bowel disease research
    • Clinical epidemiology

    Context:

    • Crohn's disease (CD) primarily affects adults, but pediatric onset is recognized.
    • Understanding pediatric CD in specific geographic regions like Tunisia is crucial for tailored healthcare.
    • This study addresses the limited data on pediatric Crohn's disease in North Africa.

    Purpose:

    • To investigate the clinical, diagnostic, therapeutic, and evolutive features of Crohn's disease in Tunisian children.
    • To characterize the presentation and management of pediatric Crohn's disease in a Tunisian cohort.

    Summary:

    • A 10-year retrospective multicenter study (2000-2008) analyzed 43 Tunisian children with Crohn's disease.
    • Key findings include a mean age of onset of 11 years, frequent diarrhea, significant extra-digestive and perineal manifestations (53% and 30% respectively), and ileocolonic localization (46%).
    • Delayed diagnosis (over 1 year in 25%) and moderate initial flares (83%) were noted, with treatment predominantly medical (77%) or combined nutritional/medical (18.5%), often involving azathioprine (62%) for maintenance.

    Impact:

    • Highlights delayed diagnosis as a significant issue in pediatric Crohn's disease management in Tunisia.
    • Emphasizes the importance of immunosuppressive therapy and nutritional support in managing pediatric Crohn's disease.
    • Provides valuable epidemiological data for pediatric Crohn's disease in Tunisia, informing future clinical practice and research.
    Abstract

    More Related Videos

    A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease05:08

    A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

    Published on: March 1, 2022

    3.7K
    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

    Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

    Published on: August 29, 2025

    705

    Related Concept Videos

    Inflammatory Bowel Disease II: Crohn's Disease01:30

    Inflammatory Bowel Disease II: Crohn's Disease

    Introduction
    Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
    Crohn's disease
    Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
    1.6K
    Inflammatory Bowel Disease III: Crohn's Disease01:25

    Inflammatory Bowel Disease III: Crohn's Disease

    Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
    35
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
    880
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
    755
    Inflammatory Bowel Disease IV: Clinical Manifestations01:20

    Inflammatory Bowel Disease IV: Clinical Manifestations

    Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The...
    33
    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

    Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
    692